Erez Aminov Sells 55,410 Shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Stock

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) CEO Erez Aminov sold 55,410 shares of MIRA Pharmaceuticals stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $1.39, for a total value of $77,019.90. Following the sale, the chief executive officer now owns 1,105,790 shares of the company’s stock, valued at approximately $1,537,048.10. This trade represents a 4.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

MIRA Pharmaceuticals Stock Down 0.8 %

MIRA Pharmaceuticals stock traded down $0.01 during midday trading on Wednesday, reaching $1.27. The company’s stock had a trading volume of 162,354 shares, compared to its average volume of 2,151,294. The business has a 50-day simple moving average of $1.34 and a 200-day simple moving average of $1.32. The company has a market cap of $21.03 million, a P/E ratio of -2.29 and a beta of 3.09. MIRA Pharmaceuticals, Inc. has a fifty-two week low of $0.51 and a fifty-two week high of $5.01.

MIRA Pharmaceuticals (NASDAQ:MIRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. As a group, equities analysts forecast that MIRA Pharmaceuticals, Inc. will post -0.6 earnings per share for the current year.

Hedge Funds Weigh In On MIRA Pharmaceuticals

An institutional investor recently raised its position in MIRA Pharmaceuticals stock. Virtu Financial LLC grew its holdings in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) by 330.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 63,055 shares of the company’s stock after purchasing an additional 48,397 shares during the quarter. Virtu Financial LLC owned about 0.43% of MIRA Pharmaceuticals worth $69,000 as of its most recent filing with the Securities and Exchange Commission. 35.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have commented on MIRA. RODMAN&RENSHAW raised shares of MIRA Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Ascendiant Capital Markets began coverage on shares of MIRA Pharmaceuticals in a report on Monday, August 5th. They set a “buy” rating and a $11.00 target price for the company. Finally, Rodman & Renshaw started coverage on shares of MIRA Pharmaceuticals in a research note on Monday, September 30th. They set a “buy” rating and a $17.00 price objective on the stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.